XELSTRYM, The First-and-Only Amphetamine Patch for the Treatment of ADHD Now Comes with an Optional Support App

MIAMI & JERSEY CITY, N.J. --(BUSINESS WIRE)

Noven Pharmaceuticals, Inc., (Noven), a wholly owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., anda leader in pharmaceutical innovation, is proud to announce the launch of its groundbreaking app, Mindful Patch, at APSARD 2025 Annual Conference, taking place from January 16th – 19th in San Diego, California.

This innovative app marks a significant milestone in our patient-centric care by empowering patients to partner with their healthcare provider to analyze their individual ADHD management and organize their patch application schedules accordingly. "At Noven, we view medication as one important piece of the puzzle in addressing patient needs. We are excited to take this step toward advancing care that considers the whole person,” said Michele Geller, Director of Digital Portfolio & Project Management at Noven.

Designed to help adult ADHD patients with XELSTRYM to start and stay on track with their treatment, Mindful Patch offers features such as:

  • Set and monitor medication schedules: Customizable patch application and removal reminders help patients with their personalized treatment plan they have determined with their health care provider
  • Keep up-to-date: With real-time tracking of their daily activities, the Mindful Patch app gives patients insights via user-friendly dashboard.
  • Assist the treatment journey and access savings: Access savings offers and educational resources along the way.

“Mindful Patch is the result of deep collaboration with patients, clinicians, and developers,” said Michele Geller. “We are thrilled to unveil this app to help support patients taking XELSTRYM.”

The debut at APSARD will include an interactive demonstration of Mindful Patch at Booth #10 & #11 and a feature in the session titled Tailored Treatment for Adults With ADHD on Friday, January 17, 2025 at 9:45 am. Attendees will have the opportunity to explore the features of XELSTRYM and learn about the app’s capabilities and hear insights from industry leaders.

“Helping patients manage their ADHD conditions requires a multifaceted approach, and this app is a great first step in supporting patients with digital tools that may help them stay on course,” said Dr. Jacob Behrens, Board Certified Psychiatrist. “I look forward to continue to provide feedback as Noven's digital tools develop further.”

Learn more about Mindful Patch by visiting https://www.xelstrym.com/ or download the app from the Apple App Store or Google Play Store.

About XELSTRYM™

XELSTRYM is the first and only FDA-approved, once-daily amphetamine transdermal patch for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older. XELSTRYM should be removed within 9 hours after application.

About Noven Pharmaceuticals, Inc.

Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of prescription pharmaceutical products. Noven’s mission is to develop and offer pharmaceutical products that meaningfully benefit patients around the world, with a commitment to advancing patient care through transdermal drug delivery. Noven is a standalone operating subsidiary of Japan-based Hisamitsu Pharmaceutical Co., Inc., serving as Hisamitsu’s U.S. platform for prescription pharmaceuticals, and helping Hisamitsu bring the benefits of patch therapy to the world. For more information about Noven, visit http://www.noven.com. For information about Hisamitsu, visit https://global.hisamitsu.

Natalie Andrade
Sr. Manager – Digital Marketing & Communications
305-282-7950
[email protected]

Copyright Business Wire 2025

Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]